| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| GRN Gene Therapy(Eli Lilly And Company) | PR-006; LY3884963 | Phase 2 Clinical | Eli Lilly And Company | Frontotemporal Dementia | Details |
| TAK-594 | DNL-593; PTV:PGRN; TAK-594 | Phase 2 Clinical | Denali Therapeutics Inc | Frontotemporal Dementia | Details |
| AVB-101 | AVB-101 | Phase 2 Clinical | AviadoBio Ltd | Frontotemporal Dementia | Details |
| Nivisnebart | AL-101; GSK-4527226 | Phase 2 Clinical | Alector Inc | Alzheimer Disease; Amyotrophic Lateral Sclerosis; Frontotemporal Dementia; Nerve Degeneration; Parkinson Disease | Details |
| PBFT-02 | PBFT-02 | Phase 2 Clinical | University Of Pennsylvania | Frontotemporal Dementia | Details |
| VGN-R13 | VGN-R13 | Phase 1 Clinical | Shanghai Vitalgen BioPharma Co Ltd | Amyotrophic Lateral Sclerosis | Details |
| AG-01(A&G Pharm) | AG-01(A&G Pharm) | Phase 1 Clinical | A&G Pharmaceutical | Carcinoma, Non-Small-Cell Lung; Mesothelioma; Triple Negative Breast Neoplasms | Details |